GERD with esophagitis means that stomach acid is washing back into the esophagus frequently enough to cause visible damage to its lining. While many people with gastroesophageal reflux disease have symptoms without detectable tissue injury, roughly 40 to 60 percent of those who undergo endoscopy show no erosions at all, leaving a sizable minority who do have mucosal breaks, ulceration, or deeper inflammation that a gastroenterologist can see and grade on camera. The distinction matters because erosive esophagitis carries a higher risk of complications, responds differently to treatment, and often requires longer-term medication than reflux without visible damage.
What Actually Damages the Esophageal Lining
Acid alone is not the whole story. Pepsin, a digestive enzyme activated in the stomach, dramatically amplifies the harm. When researchers exposed esophageal tissue to acid at a pH below 3.0 along with pepsin, the damage became irreversible within about 15 minutes, whereas acid by itself produced a lesion that the tissue could fully recover from in the same timeframe.1PubMed. The role of pepsin in acid injury to esophageal epithelium Pepsin attacks the junctions between cells in the esophageal wall, weakening the barrier that normally keeps corrosive contents out of deeper tissue layers.
In people with a hiatal hernia, the problem compounds. The hernia separates the lower esophageal sphincter from the diaphragm, and the wider that gap grows, the more frequently the sphincter relaxes on its own and lets reflux through. One study found that hernia patients had roughly double the rate of these spontaneous relaxations compared with people who had no hernia, and the relaxation frequency correlated tightly with the size of the separation.2PubMed. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia This is one reason hiatal hernias and erosive esophagitis so often travel together.
Microscopic Damage Can Precede Visible Erosions
Before a gastroenterologist can see any erosion through the endoscope, the tissue is already changing at a cellular level. The spaces between esophageal lining cells widen, a finding known as dilated intercellular spaces. This widening appeared in patients with heartburn regardless of whether they had visible erosions, and it was absent in healthy controls.3BMC Gastroenterology. Dilated intercellular spaces: A morphological feature of acid reflux– damaged human esophageal epithelium Pediatric data showed the same pattern: every child diagnosed with histological esophagitis had dilated intercellular spaces, and a specific cutoff value for those spaces identified reflux disease with 100 percent specificity.4PubMed. Dilated intercellular spaces: a major morphological feature of esophagitis
These widened gaps let acid, pepsin, and other irritants seep deeper into the esophageal wall, sensitizing nerve endings and triggering pain even before the tissue looks damaged on a standard scope. This helps explain why some people feel terrible heartburn but have a “normal” endoscopy: the damage is real, just not yet visible at the surface.
How Doctors Grade Erosive Esophagitis
When an endoscopy reveals mucosal breaks, they are graded using the Los Angeles (LA) classification, a system introduced at a 1994 gastroenterology congress that has become the global standard.5PubMed Central. Endoscopic Experience Improves Interobserver Agreement in the Grading of Esophagitis by Los Angeles Classification: Conventional Endoscopy and Optimal Band Image System The grades run from A through D:
- Grade A: one or more mucosal breaks no longer than 5 mm, none extending between the tops of two mucosal folds.
- Grade B: at least one mucosal break longer than 5 mm, still not spanning between two fold tops.
- Grade C: mucosal breaks extending between two or more fold tops but covering less than 75 percent of the esophageal circumference.
- Grade D: mucosal breaks covering 75 percent or more of the circumference.
The grade matters for treatment planning. Higher grades predict a weaker response to therapy and a greater chance of relapse once treatment stops.6PubMed Central. Endoscopic evaluation of gastro-esophageal reflux disease Grades C and D are considered severe, and these patients typically need more aggressive medication or longer courses to heal.
Heartburn Severity Is a Poor Predictor of Tissue Damage
One of the most counterintuitive findings in reflux research is that how bad your heartburn feels tells you almost nothing about how badly your esophagus is injured. In a large analysis of patients with erosive esophagitis, about a quarter had severe disease (LA grades C or D) regardless of whether their heartburn was mild, moderate, or severe. The rate of advanced erosions ran between 22 and 31 percent across all heartburn severity groups.7PubMed Central. Heartburn Severity Does Not Predict Disease Severity in Patients With Erosive Esophagitis A separate analysis confirmed that while the prevalence of severe erosive disease climbs with age, heartburn intensity remains an unreliable indicator of what the scope will show.8Gastroenterology. Relationship Among Age, Severity of Heartburn, and Severity of Erosive Esophagitis
This disconnect has real consequences. People with mild symptoms may skip evaluation, not realizing their esophagus is quietly eroding. Conversely, someone with excruciating heartburn may have a clean endoscopy. The mismatch is one reason many gastroenterologists recommend scoping patients with chronic reflux at least once, especially those over 50 or with alarm symptoms like difficulty swallowing or unexplained weight loss.
Symptoms Beyond Heartburn
Heartburn and regurgitation get most of the attention, but GERD with esophagitis can present in ways that have nothing obvious to do with the esophagus. Chronic cough is a well-recognized consequence of reflux, and researchers now use the term GERD-related chronic cough (GERC) for coughs driven primarily by gastroesophageal reflux.9PubMed Central. GERD-related chronic cough: Possible mechanism, diagnosis and treatment Other extraesophageal symptoms include hoarseness, throat clearing, a sensation of a lump in the throat, and worsening asthma. These symptoms sometimes appear without any heartburn at all, which makes GERD an easy diagnosis to miss when the presentation is primarily respiratory or laryngeal.
Pain perception also varies. Patients with erosive esophagitis show heightened sensitivity in the esophagus even before acid is introduced: their pain thresholds to balloon distention are lower than those of healthy controls, and acid exposure drops those thresholds further.10The Clinical Journal of Pain. Quantitative Assessment and Characterization of Visceral Hyperalgesia Evoked by Esophageal Balloon Distention and Acid Perfusion in Patients With Functional Heartburn, Nonerosive Reflux Disease, and Erosive Esophagitis This visceral hypersensitivity means that the nervous system in some patients amplifies signals from the esophagus, making even mild reflux feel severe.
Diagnostic Tools Beyond the Scope
Endoscopy is the first-line investigation for suspected GERD in most clinical settings, but it has a blind spot: it misses nonacid and gas reflux that still irritates the esophagus. Ambulatory 24-hour impedance-pH monitoring fills that gap by tracking acid reflux, minor acid reflux, nonacid reflux, and gas reflux over a full day and night.11PubMed. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings This test is considered the best current tool for detecting abnormal reflux and linking symptom episodes to specific reflux events.12PubMed. Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis
The test is especially useful for people whose symptoms persist on acid-suppressing medication. If the scope looks normal and a proton pump inhibitor isn’t helping, impedance-pH monitoring can reveal whether nonacid reflux is the culprit or whether the symptoms aren’t reflux-related at all. It is also the key tool for distinguishing GERD from eosinophilic esophagitis, a condition that can mimic reflux but involves a completely different mechanism.
When It Looks Like GERD but Isn’t
Eosinophilic esophagitis (EoE) is the great imitator. Both conditions can cause difficulty swallowing, and both can produce visible changes on endoscopy. But the patient profiles and the endoscopic findings are distinct. People with EoE tend to be younger (typically in their 30s or 40s), often have a history of allergies or asthma, and present with trouble swallowing solid foods or food getting stuck. Their endoscopy shows rings, furrows, and white patches rather than the flat erosions and redness typical of reflux esophagitis. GERD patients, by contrast, are more often middle-aged, respond readily to acid-suppressing drugs, and show erosive changes, Barrett metaplasia, or a hiatal hernia on scope.13PubMed Central. Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies
The distinction matters because the treatments are different. EoE responds to swallowed topical steroids and dietary elimination, not proton pump inhibitors alone. If you’ve been treated for reflux without improvement, and particularly if swallowing problems are your dominant complaint, biopsies taken during endoscopy can settle the question.
How Medications Stack Up
Proton pump inhibitors (PPIs) remain the backbone of erosive esophagitis treatment.14PubMed Central. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole Among PPIs, a meta-analysis found that esomeprazole offered a modest advantage over other options, healing about 5 percent more patients at eight weeks. The number of patients you would need to treat to see one extra healed case ranged from 50 for mild (grade A) disease down to 8 for severe (grade D) disease.15PubMed. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials Those differences are real but not enormous for mild cases, which is why your doctor may start you on whichever PPI is covered by your insurance.
A newer class of drugs, potassium-competitive acid blockers (P-CABs), is changing the landscape, especially for severe esophagitis. Network meta-analyses have found that most P-CABs achieve higher healing rates than PPIs, with the gap widening for LA grade C and D disease.16PubMed Central. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis Vonoprazan, the most-studied P-CAB, showed meaningful superiority over several older PPIs for severe grades, with risk differences in healing ranging from 5 to 15 percentage points.17The Lancet Gastroenterology & Hepatology. Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors in erosive esophagitis P-CABs work faster than PPIs because they block acid secretion through a different mechanism that does not require activation by food. Vonoprazan was approved in the United States in 2023 and is increasingly used for patients who fail standard PPI therapy or who have severe erosive disease.
Lifestyle Changes That Have Evidence Behind Them
Losing weight is the lifestyle intervention with the most robust evidence. A large population-based cohort study found a dose-dependent relationship between weight loss and reflux improvement: people who dropped more than 3.5 BMI units roughly doubled their odds of losing reflux symptoms when they were not taking regular medication, and the effect was even stronger in those already using antireflux drugs.18American Journal of Gastroenterology. Weight Loss and Reduction in Gastroesophageal Reflux. A Prospective Population-Based Cohort Study: The HUNT Study Even modest weight loss helps, but more yields more.
Sleep position is the other lifestyle factor with surprisingly strong data. Sleeping on your left side reduces both the amount of acid exposure in the esophagus and the total time acid is in contact with the lining, compared with sleeping on your right side or on your back.19PubMed Central. Left lateral decubitus sleeping position is associated with improved gastroesophageal reflux disease symptoms: A systematic review and meta-analysis This works because of anatomy: when you lie on your left, the stomach hangs below the esophageal junction, and pooled acid sits away from the valve. Raising the head of the bed by about 15 to 20 centimeters and extending the gap between dinner and bedtime round out the recommended nighttime strategy.20PubMed Central. Systematic review: Clinical effectiveness of interventions for the treatment of nocturnal gastroesophageal reflux A sequential approach of head elevation, longer dinner-to-bed time, left-side sleeping, and acid-suppressing medication tends to work better than any single measure alone.
Where Untreated Esophagitis Can Lead
Erosive esophagitis that goes unchecked can progress in two main directions, both involving the body’s attempt to repair chronic injury. Deep or repeated ulceration triggers scar tissue and collagen buildup that can narrow the esophageal channel, forming a stricture that makes swallowing difficult.21PubMed. Clinical manifestations and esophageal complications of GERD Strictures require dilation procedures and long-term acid suppression to prevent recurrence.
The other complication is Barrett’s esophagus, in which the normal tissue lining the lower esophagus is replaced by a type of cell that usually lines the intestine. Barrett’s develops as a complication of chronic reflux and is a recognized risk factor for esophageal adenocarcinoma, a cancer whose incidence has been rising in developed countries.22The Lancet. Barrett’s oesophagus The actual risk of any individual with Barrett’s progressing to cancer is low on a year-to-year basis, but the diagnosis triggers a surveillance schedule of periodic endoscopies to catch precancerous changes early.
Surgical and Device Options
When medications don’t adequately control symptoms or when someone doesn’t want to take pills indefinitely, surgery enters the conversation. The Nissen fundoplication, where the top of the stomach is wrapped around the lower esophagus to reinforce the valve, has been the gold standard for decades. A newer alternative is the magnetic sphincter augmentation (MSA) device, a ring of magnetic beads placed around the lower esophageal sphincter laparoscopically.
In a comparative study, MSA procedures took substantially less operating time than Nissen fundoplication and patients returned to a normal diet much sooner, typically within a month versus three months. MSA patients also retained the ability to belch at a much higher rate, which is a common complaint after Nissen wraps. About half of patients in both groups experienced some degree of swallowing difficulty after surgery, though none required endoscopic dilation.23PubMed Central. A comparative study of magnetic sphincter augmentation and Nissen fundoplication in the management of GERD Neither procedure is perfect, and both carry the risk of needing revision, but they offer a path off lifelong medication for the right candidates.
The Esophageal Microbiome and Inflammation
A less well-known dimension of erosive esophagitis involves changes to the microbial community living on the esophageal lining. In a healthy esophagus, gram-positive bacteria dominate. In esophagitis and Barrett’s esophagus, the balance shifts toward gram-negative species.24PubMed Central. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus Gram-negative bacteria carry lipopolysaccharides on their outer membranes, and these molecules activate inflammatory pathways that ramp up the production of pro-inflammatory signaling proteins in the esophageal tissue.25Clinical Cancer Research. Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus
What makes this especially interesting is that these bacterial products may also worsen reflux itself by relaxing the lower esophageal sphincter and slowing stomach emptying. This creates a potential feedback loop: reflux damages the lining, the damaged lining fosters a gram-negative-heavy microbial population, and those bacteria generate substances that promote more reflux. Research in this area is still early, and no microbiome-based therapies have emerged for esophagitis, but the altered microbial community in Barrett’s esophagus has drawn attention for its possible role in progression toward esophageal cancer.26PubMed Central. Microbiome, innate immunity, and esophageal adenocarcinoma
The Cost and Burden of Erosive Esophagitis
Erosive esophagitis is not just a clinical problem; it carries a significant economic footprint. A national retrospective cohort study in the United States found that average total all-cause costs for patients undergoing endoscopy were nearly $59,000 per patient, with about $4,300 of that directly attributable to erosive esophagitis management.27Diseases of the Esophagus. Economic and treatment burden among newly diagnosed patients with erosive esophagitis in the US: a national retrospective cohort study Much of that cost comes from a pattern of cycling and switching among PPIs: patients try one, don’t get full relief, switch to another, sometimes stop treatment altogether, then start again. About one in five patients who had an endoscopy showing erosive disease never filled a PPI prescription at all.
This cycling behavior matters because erosive esophagitis relapses frequently once medication stops. A cost-effectiveness analysis found that starting maintenance PPI therapy right away rather than waiting for a relapse made economic sense whenever reflux symptoms caused even a modest hit to quality of life, defined as roughly a 2 percent decrement on a quality-adjusted scale.28PubMed. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition Given that most people with erosive disease report substantially more than a 2 percent quality-of-life impact, the finding suggests that the current pattern of intermittent treatment wastes money and prolongs suffering. Consistent, guideline-based therapy from the start tends to be both cheaper and more effective than the stop-start approach many patients fall into.